Stepwise increase of fidaxomicin in an engineered heterologous host Streptomyces albus through multi-level metabolic engineering

The anti-Clostridium difficile infection (CDI) drug fidaxomicin is a natural polyketide metabolite mainly produced by Micromonosporaceae, such as Actinoplanes deccanensis, Dactylosporangium aurantiacum, and Micromonospora echinospora. In the present study, we employed a stepwise strategy by combinin...

Full description

Bibliographic Details

Published in:	Synthetic and Systems Biotechnology
Main Authors:	Huang Xie, Yi-Ting Su, Qing-Ting Bu, Yue-Ping Li, Qing-Wei Zhao, Yi-Ling Du, Yong-Quan Li
Format:	Article
Language:	English
Published:	KeAi Communications Co., Ltd. 2024-12-01
Subjects:	Fidaxomicin Heterologous expression Streptomyces albus Genome-reduced chassis Metabolic engineering
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405805X24000930